---
title: "Artiva Biotherapeutics, Inc. (ARTV.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ARTV.US.md"
symbol: "ARTV.US"
name: "Artiva Biotherapeutics, Inc."
industry: "生物技术"
---

# Artiva Biotherapeutics, Inc. (ARTV.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.artivabio.com](https://www.artivabio.com) |

## Company Profile

Artiva Biotherapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发基于自然杀伤（NK）细胞的疗法，旨在为患有自身免疫疾病和癌症的患者提供治疗。该公司的主要产品候选包括 AlloNK，这是一种现成的 NK 细胞疗法，适用于患有自身免疫疾病和癌症的患者，如类风湿性关节炎、系统性红斑狼疮、狼疮性肾炎、类风湿性关节炎、天疱疮、抗中性粒细胞胞浆抗体相关血管炎亚型的肉芽肿性多血管炎/显微镜下多血管炎，以及 B 细胞非霍奇金淋巴瘤。它还开发了 AB-201，这是一种针对人类表皮生长因子受体 2 的同种异体嵌合抗原受体（CAR）-NK 细胞产品候选，用于治疗各种实体肿瘤，如乳腺癌...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-27T04:30:18.000Z

**Overall: D (0.73)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 265 / 399 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -29.23% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.04 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 133.77M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 0.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -47.96% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -29.23% | D |
| Total Assets YoY | -34.01% | E |
| Net Assets YoY | -35.71% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 13.19% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Artiva Biotherapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-47.96%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-29.23%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-34.01%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-35.71%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "13.19%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.69 | 238/602 | - | - | - |
| PB | 1.04 | 83/602 | 0.76 | 0.48 | 0.30 |
| PS (TTM) | 203.83 | - | 203.83 | 203.83 | 203.83 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 83% |
| Overweight | 1 | 17% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.82 |
| Highest Target | 23.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ARTV.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ARTV.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ARTV.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.